BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Windtree Therapeutics Inc. /de/ WINT
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
—
Dividend / sh · FY24
—
Payout · FY24
-37%
ROE · FY24
-26.7%
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 15-year series below
Revenue
Net income
Per share
—
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-26.7%
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets-5.9%
Each USD of equity lost 27 cents this year.
Returned to shareholders
USD 657,000.00
returned in FY2024 · dividends + net buybacks
Dividends paidUSD 657,000.00
Net buybacks—
Share of profit-36.8%
Consecutive raises—
USD 657,000.00 in dividends went back to shareholders in a year without profit.
Growth
−41.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−54.1%
−41.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 27.9M
total assets, end of FY2024
Total assetsUSD 27.9M
EquityUSD 10.0M
CashUSD 1.8M
Current ratio0.45×
Equity funds 36% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
−0.0
−0.0
0.0
·
·
·
·
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
−2.73
−2.08
−2.51
−7.74
−24.14
−94.84
−7.98
−7.84
−0.82
−0.95
−0.93
−1.65
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
−37
−0
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−26.7
−302.8
−151.1
−121.4
−45.1
−38.4
−92.9
·
·
−401.7
−113.4
−118.7
−394.5
−575.2
−318.2
Shares out B
0.00
0.00
0.00
0.00
0.02
0.01
0.03
0.00
0.00
0.01
0.01
0.08
0.04
0.02
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
45 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed